Genprex

Monthly Archives: January 2017

Genprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex™ for Late Stage Non-Small Cell Lung Cancer

AUSTIN, TX, January 6, 2017 – Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®) for the treatment of late stage non-small cell lung cancer (NSCLC) patients.

The clinical trial, which is ongoing at The University of Texas MD Anderson Cancer Center, is designed to evaluate the Oncoprex/erlotinib treatment combination in up to 57 patients with late stage NSCLC, with and without EGFR mutations, who have failed at least two drug regimens….

Read More